Ahmet Tutuncu

Ahmet Tutuncu has more than 25 years of experience in academic/medical practice and the pharmaceutical industry. Prior to Respivant, Dr. Tutuncu was most recently a co-founder and the CMO of Patara Pharma. Prior to Patara, he was co-founder and CMO of Elevation Pharmaceuticals, responsible for the execution of multiple Phase 2 clinical trials for a new therapy to treat severe COPD. Prior to Elevation, Dr. Tutuncu was VP of Medical Affairs at Verus Pharma where he was responsible for all clinical development activities targeted at asthma, anaphylaxis and other atopic conditions. Prior to joining Verus, Dr. Tutuncu was Director of Corporate Medical Affairs at SkyePharma where he led the clinical development of pulmonary programs including budesonide, formoterol and FlutiForm®. Previously, Dr. Tutuncu held positions of increasing responsibility in clinical development and drug safety at Alliance Pharmaceuticals. He received his Ph.D. in Respiratory Pathophysiology from Erasmus University Rotterdam and his M.D. from the University of Istanbul where he was also an attending physician and faculty member specializing in intensive care medicine.